Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

NCT06580574 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Colon Cancer
MSI-H
DMMR Cancer

Interventions

DRUG: PD1/PDL1 antibody monotherapy, up to 24 weeks
COMBINATION_PRODUCT: Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks
PROCEDURE: Radical surgery

Sponsor

Peking University